当前位置: X-MOL 学术Cancer Biother. Radiopharm. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
First Ex Vivo Results of β−-Radioguided Surgery in Small Intestine Neuroendocrine Tumors with 90Y-DOTATOC
Cancer Biotherapy and Radiopharmaceuticals ( IF 2.4 ) Pub Date : 2021-06-09 , DOI: 10.1089/cbr.2020.4487
Emilio Bertani 1 , Francesco Collamati 2 , Marzia Colandrea 3 , Riccardo Faccini 2, 4 , Nicola Fazio 5 , Mahila E Ferrari 6 , Marta Fischetti 2, 7 , Uberto Fumagalli Romario 1 , Luigi Funicelli 8 , Micol De Simoni 2, 4 , Carlo Mancini-Terracciano 2, 4 , Riccardo Mirabelli 2, 4 , Silvio Morganti 2 , Stefano Papi 3 , Eleonora Pisa 9 , Elena Solfaroli-Camillocci 2, 10 , Francesca Spada 5 , Marta Cremonesi 6 , Chiara M Grana 3
Affiliation  

Background: In neuroendocrine tumor (NET), complete surgery could better the prognosis. Radioguided surgery (RGS) with β-radioisotopes is a novel approach focused on developing a new probe that, detecting electrons and operating with low background, provides a clearer delineation of the lesions with low radiation exposition for surgeons. As a first step to validate this procedure, ex vivo specimens of tumors expressing somatostatin receptors, as small intestine neuroendocrine tumor (SI-NET), were tested.

中文翻译:

使用 90Y-DOTATOC 在小肠神经内分泌肿瘤中进行 β--放射引导手术的首次体外结果

背景:在神经内分泌肿瘤(NET)中,完整的手术可以更好地预后。使用 β -放射性同位素的放射引导手术 (RGS)是一种专注于开发新探针的新方法,该探针可检测电子并在低背景下操作,为外科医生提供更清晰的病变轮廓,同时低辐射暴露。作为验证该程序的第一步,测试了表达生长抑素受体的肿瘤的离体标本,如小肠神经内分泌肿瘤 (SI-NET)。
更新日期:2021-06-11
down
wechat
bug